MetaSight Diagnostics builds multi-omics screening and diagnostic products using a high-throughput, mass spectrometry–based discovery engine that integrates metabolomics, lipidomics and proteomics. The company claims the world’s largest serum metabolomics dataset linked to longitudinal electronic medical records and uses that dataset to identify diagnostic signatures at population scale. Its core programs target diseases including colorectal cancer (CRC) and metabolic dysfunction‑associated steatohepatitis (MASH). MetaSight plans to advance existing programs into FDA trials and expand its portfolio of diagnostic products. The company intends to make its tests available in selected markets in 2025 and is engaging in strategic partnerships to support commercialization. MetaSight was founded in 2021 and is headquartered in Rehovot, Israel. The Series A will fund pipeline development and additional strategic collaborations.

Total raised

$8M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2024